BioCentury
ARTICLE | Clinical News

FDA approves Aimovig as first CGRP inhibitor for migraines

May 18, 2018 7:42 PM UTC

FDA approved Aimovig erenumab from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) late on May 17 to prevent migraine in adults. The drug is the first calcitonin gene-related peptide (CGRP) inhibitor approved for the indication.

Amgen said it expects to launch Aimovig within a week at an annual wholesale acquisition cost (WAC) of $6,900...

BCIQ Company Profiles

Amgen Inc.

Novartis AG